The Cooper Companies news

The company is under investigation for issuing materially misleading business information, released disappointing earnings with weak guidance, and experienced a significant 14.6% stock price decline on the news.

Company missed Q3 revenue expectations by $30 million, reported flat CooperVision segment growth, announced inventory reductions impacting Q4 guidance, and faced a significant 14.7% stock price decline. Additionally, the company is subject to a securities investigation regarding potential violations of federal securities laws.

The company received a Zacks Rank #5 (Strong Sell) rating, indicating expected underperformance. Asia Pacific revenues missed analyst expectations by 6.14%, and the stock has declined 29.2% over the past month, significantly underperforming the broader market. While EMEA beat expectations slightly, overall revenue growth remains minimal at 0.6% YoY, and the company faces headwinds from currency fluctuations and geopolitical uncertainties.

Stock declined 14.6% following earnings that revealed significant channel inventory destocking, downward revenue guidance revision, and triggered a securities investigation by Hagens Berman regarding potential lack of transparency about sales practices and sustainability of reported growth.

While adjusted EPS beat estimates, revenues missed expectations and the stock declined 15.9% after-hours. CooperVision faces ongoing U.S. inventory destocking pressures expected to continue into Q4, margin compression from higher manufacturing costs and FX headwinds, and weakness in Asia Pacific. The company has a Zacks Rank #4 (Sell) rating.

Despite expected growth drivers from CooperVision and CooperSurgical, the company carries a Zacks Rank #4 (Sell) with 0% Earnings ESP, indicating no conclusive earnings beat predicted. Stock has underperformed significantly, down 17.4% YTD versus industry growth of 7.3%. Persistent Asia Pacific headwinds, margin pressures from FX and tariffs, and modest EPS growth of only 0.9% present concerns.

Marginally beat earnings estimate ($1.15 vs $1.11 consensus) but missed revenue estimate by 2.97%, showing mixed performance with modest earnings growth.

Marginally beat earnings estimate ($1.15 vs $1.11 expected) but missed revenue estimate by 2.97%, showing mixed performance with modest earnings growth.

Reported Q2 fiscal 2026 adjusted EPS of $1.21 beating consensus by 10%, revenues of $1.08 billion beat estimates by 2.6%, carries Zacks Rank #2 (Buy), has 8.3% estimated long-term earnings growth rate, and beat estimates in all trailing four quarters with 5.8% average surprise.